Incorporation of pseudocapsule presence into a modified Clear Cell Likelihood Score (m-ccLS) was associated with a greater than 11 percent higher AUC in differentiating benign and malignant renal masses on mpMRI, according to a new study.
|Articles|November 20, 1996
HP inks catheter deal with Guidant
Hewlett-Packard has signed an agreement with Guidant of Indianapolisgiving that cardiology device company rights to distribute coronaryand peripheral intravascular ultrasound catheters that HP haslicensed from Boston Scientific. HP executed the deal
Advertisement
Hewlett-Packard has signed an agreement with Guidant of Indianapolisgiving that cardiology device company rights to distribute coronaryand peripheral intravascular ultrasound catheters that HP haslicensed from Boston Scientific. HP executed the deal becauseit believes that Guidant's distribution channels are more suitedfor the IVUS market than its own, according to the Andover, MA,company.
HP gained access to the catheters through an agreement lastyear with Boston Scientific, which at the time was preparing tobuy catheter developers Cardiovascular Imaging Systems and ScimedLife Systems. To avoid a monopoly in the IVUS market, the FederalTrade Commission required Boston Scientific to enter a consentdecree in which it licensed the technology to a third party, Hewlett-Packard(SCAN 3/15/95).
HP already has a deal with Guidant for development of guideddirectional atherectomy catheters. Guidant also has rights todistribute Hewlett-Packard's Sonos Intravascular Ultrasound Systemwith the catheters.
Advertisement
Related to this article
For patients with hepatocellular carcinoma (HCC), perfusion beyond tumor margin on contrast-enhanced ultrasound that exceeds gray-scale ultrasound tumor measurement by 5 mm is associated with a 76 percent higher risk of worse recurrence-free survival, according to newly published research.
In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the utility of prostatic artery embolization for treating benign prostatic hyperplasia, key imaging considerations and pertinent technique pearls to help facilitate optimal outcomes.
The AI-powered SwiftSight Body Composition software reportedly provides automated quantification of muscle and adipose tissue after a brief MRI scan.
In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.
Has the barrage of passwords, PINs and authenticator apps gone around the bend to a point where it hampers efficiency and productivity?
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Body Composition Analysis
2
Study Shows Impact of Key mpMRI Features for Enhancing Assessment of Renal Masses
3
Tumor Margin Marker on Contrast-Enhanced Ultrasound May Predict Worse Outcomes in Patients with HCC
4
Interventional Radiology in Focus: A Closer Look at Prostatic Artery Embolization for Benign Prostatic Hyperplasia
5